The concurrent inhibition of DNMT and HDAC while less studied in CRC, has exhibited promising preliminary clinical efficacy in other solid cancer types, indicative of its therapeutic potential in patients72–74. The gene discussed is DNMT1; the disease is colorectal carcinoma.